Allogeneic Th1 Memory Cell Vaccines for Immune Priming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current active immunotherapy technologies fail to effectively elicit Th1 immune responses necessary for cancer therapy and protection against viral diseases like HIV/AIDS and Hepatitis C, as they predominantly promote Th2 responses, which are not sufficient for tumor eradication and viral defense.
Innovation Solution
The use of allogeneic activated Th1 memory cells to prime individuals, creating a Th1 footprint that can be activated later to mount a strong immune response, overcoming tumor immunoavoidance mechanisms and enhancing the immune system's ability to combat cancer and infectious diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccine compositions are used to elicit immune responses, then Th2 or humoral immune responses are generated, but Th1 immune activation is insufficient for effective cancer therapy and viral disease protection
Solution Approach 1:
The patent changes the immunological parameter by using allogeneic Th1 memory cells as adjuvants, which fundamentally alters the type of immune response generated. Instead of conventional Th2-dominant responses, the composition induces Th1-dominant responses with high IFN-gamma production, thereby improving effectiveness against cancer and viral diseases.
Solution Approach 2:
The patent introduces allogeneic Th1 memory cells as an intermediary substance that mediates the immune response. These cells act as adjuvants that steer the host's immune system toward Th1 responses, providing the necessary Th1 activation for effective therapy while avoiding the limitations of Th2 responses.
2Reliability
If Th1 immune activation is achieved through active immunotherapy, then anti-tumor effector mechanisms are upregulated, but tumor immunoavoidance mechanisms still allow unimpeded tumor growth
Solution Approach 1:
The patent applies preliminary action by administering allogeneic Th1 memory cells before the actual tumor challenge or as part of the immunotherapy protocol. This pre-activation of Th1 responses and expansion of Th1 footprints in the host prepares the immune system to better confront tumor immunoavoidance mechanisms, enhancing the overall efficacy of anti-tumor therapy.
3Quantity of substance
If allogeneic Th1 memory cells are used to prime individuals, then Th1 footprint is increased in circulation, but the complexity of the vaccination protocol is increased
Solution Approach 1:
The patent achieves universality by using allogeneic Th1 memory cells that can serve multiple functions: they act as adjuvants to steer immune responses, provide immediate Th1 activation, and can be used across different disease contexts (cancer, viral infections). This multi-functionality justifies the protocol complexity by delivering multiple benefits from a single cellular product.
Data Source
AI summary
The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.